Trastuzumab deruxtecan heralds new era in the treatment of metastatic breast cancer ; Трастузумаб дерукстекан – новая эпоха терапии метастатического рака молочной железы

Authors: E. V. Lubennikova, E. V. Artamonova, Е. В. Лубенникова, Е. В. Артамонова

Source: Meditsinskiy sovet = Medical Council; № 11 (2023); 26-33 ; Медицинский Совет; № 11 (2023); 26-33 ; 2658-5790 ; 2079-701X

Subject Terms: лекарственный пульмонит, conjugate, breast cancer, metastatic breast cancer, Her2-positive breast cancer, Her2-low breast cancer, CNS metastatic disease, drug-induced pulmonitis, конъюгат, рак молочной железы, метастатический рак молочной железы, Her2-позитивный рак молочной железы, Her2-Low рак молочной железы, метастатическое поражение ЦНС

File Description: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7665/6799; Baselga J., Cortés J., Kim S.B., Im S.A., Hegg R., Im Y.H. et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–119. https://doi.org/10.1056/NEJMoa1113216.; Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M. et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724–734. https://doi.org/10.1056/NEJMoa1413513.; Nicolò E., Zagami P., Curigliano G. Antibody–drug conjugates in breast cancer: the chemotherapy of the future? Curr Opin Oncol. 2020;32(5):494–502. https://doi.org/10.1097/CCO.0000000000000656.; Schettini F., Chic N., Brasó-Maristany F., Paré L., Pascual T., Conte B. et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. NPJ Breast Cancer. 2021;7(1):1. https://doi.org/10.1038/s41523-020-00208-2.; Tarantino P., Hamilton E., Tolaney S.M., Cortes J., Morganti S., Ferraro E. et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol. 2020;38(17):1951–1962. https://doi.org/10.1200/JCO.19.02488.; Nakada T., Sugihara K., Jikoh T., Abe Y., Agatsuma T. The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull. 2019;67(3):173–185. https://doi.org/10.1248/cpb.c18-00744.; Modi S., Saura C., Yamashita T., Park Y.H., Kim S.-B., Tamura K. et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. N Engl J Med. 2020;382(7):610–621. https://doi.org/10.1056/NEJMoa1914510.; Ogitani Y., Hagihara K., Oitate M., Naito H., Agatsuma T. Bystander killing effect of DS‐8201a, a novel anti‐human epidermal growth factor receptor 2 antibody–drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016;107(7):1039–1046. https://doi.org/10.1111/cas.12966.; Mosele M.F., Lusque A., Dieras V., Deluche E., Ducoulombier A., Pistilli B. et al. LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): biomarker analyses from patients from DAISY trial. Ann Oncol. 2022;33:S123. https://doi.org/10.1016/j.annonc.2022.03.277; Diéras V., Deluche E., Lusque A., Pistilli B., Bachelot T., Pierga J.Y. et al. Abstract PD8-02: Trastuzumab deruxtecan (T-DXd) for advanced breast cancer patients (ABC), regardless HER2 status: a phase II study with biomarkers analysis (DAISY). Cancer Research. 2022;82:(4 Suppl):PD8–02. https://doi.org/10.1158/1538-7445.SABCS21-PD8-02.; Manich C.S., Modi S., Krop I., Park Y.H., Kim S.B., Tamura K. et al. 279P trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2021;32:S485–S486. https://doi.org/10.1016/j.annonc.2021.08.562.; Saura Manich C., Modi S., Krop I., Park Y.H., Kim S., Tamura K. et al. Trastuzumab deruxtecan (T-DXd) in patients with HER2-positive metastatic breast cancer (MBC): Updated survival results from a phase II trial (DESTINY-Breast01). Ann Oncol. 2021;32(5 Suppl.):S485–S486. https://doi.org/10.1016/j.annonc.2021.08.562.; André F., Hee Park Y., Kim S.B., Takano T., Im S.A., Borges G. et al. Trastuzumab deruxtecan versus treatment of physician’s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;401(10390): 1773–1785. https://doi.org/10.1016/S0140-6736(23)00725-0.; André F., Shahidi J., Lee C., Wang K., Krop I.E. Trastuzumab deruxtecan (DS-8201a) vs investigator’s choice of treatment in subjects with HER2- positive, unresectable and/or metastatic breast cancer who previously received T-DM1: A randomized, phase 3 study. Cancer Research. 2019;79(4):OT2-07-02. https://doi.org/10.1158/1538-7445.SABCS18-OT2-07-02.; Hurvitz S.A., Hegg R., Chung W-P., Im S-A., Jacot W., Ganju V. et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINYBreast03, a randomised, open-label, phase 3 trial. Lancet. 2023;401(10371): 105–117. https://doi.org/10.1016/S0140-6736(22)02420-5.; Curigliano G., Dunton K., Rosenlund M., Janek M., Cathcart J., Liu Y. et al. Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase 3 DESTINY-Breast03 study. Ann Oncol. 2023;(23):00677-4. https://doi.org/10.1016/j.annonc.2023.04.516.; Garcia-Alvarez A., Papakonstantinou A., Oliveira M. Brain metastases in HER2-positive breast cancer: current and novel treatment strategies. Cancers. 2021;13(12):2927. https://doi.org/10.3390/cancers13122927.; Watase C., Shiino S., Shimoi T., Noguchi E., Kaneda T., Yamamoto Y. et al. Breast cancer brain metastasi s– overview of disease state, treatment options and future perspectives. Cancers. 2021;13(5):1078. https://doi.org/10.3390/cancers13051078.; Bailleux C., Eberst L., Bachelot T. Treatment strategies for breast cancer brain metastases. Br J Cancer. 2021;124(1):142–155. https://doi.org/10.1038/s41416-020-01175-y.; Jerusalem G., Park Y.H., Yamashita T., Hurvitz S.A., Modi S., Andre F. et al. Trastuzumab Deruxtecan in HER2-positive metastatic breast cancer patients with brain metastases: a DESTINY-Breast01 subgroup analysis. Cancer discovery. 2022;12(12):2754–2762. https://doi.org/10.1158/2159-8290.CD-22-0837.; Jacobson A. Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases. Oncologist. 2022;27(Suppl 1):S3–S4. https://doi.org/10.1093/oncolo/oyac009.; Pérez-García J.M., Vaz Batista M., Cortez P., Ruiz-Borrego M., Cejalvo J.M., de la Haba-Rodriguez et al. Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: the DEBBRAH trial. Neuro Oncol. 2023;25(1):157–166. https://doi.org/10.1093/neuonc/noac144.; Ogitani Y., Aida T., Hagihara K., Yamaguchi J., Ishii C., Harada N. et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1Preclinical Efficacy of DS-8201a, a Novel HER2-Targeting ADC. Clin Cancer Res. 2016;22(20):5097–5108. https://doi.org/10.1158/1078-0432.CCR-15-2822.; Modi S., Jacot W., Yamashita T., Sohn J., Vidal M., Tokunaga E. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. https://doi.org/10.1056/NEJMoa2203690.; Powell C.A., Modi S., Iwata H., Takahashi S., Smit E.F., Siena S. et al. Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies. ESMO Open. 2022;7(4):100554. https://doi.org/10.1016/j.esmoop. 2022.100554.; Tarantino P., Modi S., Tolaney S.M., Cortés J., Hamilton E.P., Kim S.B. et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7(12):1873–1881. https://doi.org/10.1001/jamaoncol.2021.3595.; Powell C.A., Modi S., Iwata H., Takahashi S., Smit E.F., Siena S. et al. Pooled analysis of drug-related interstitial lung disease (ILD) in 8 single-arm trastuzumab deruxtecan (T-DXd) studies. ESMO Open. 2022;7(4):100554. https://doi.org/10.1016/j.esmoop.2022.100554.; Conte P., Ascierto P.A., Patelli G., Danesi R., Vanzulli A., Sandomenico F. et al. Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment. ESMO open. 2022;7(2):100404. https://doi.org/10.1016/j.esmoop.2022.100404.; Powell C.A., Modi S., Iwata H., Takahashi S., Nie K., Qin A. et al. Analysis of study drug-related interstitial lung disease (ILD) in patients (pts) with HER2+ metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd). Ann Oncol. 2021;32:S61–S62. https://doi.org/10.1016/j.annonc.2021.03.106.; Kumagai K., Aida T., Tsuchiya Y., Kishino Y., Kai K., Mori K. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab–drug conjugate, in monkeys. Cancer Sci. 2020;111(12):4636–4645. https://doi.org/10.1111/cas.14686.; Rugo H.S., Bianchini G., Cortes J., Henning J.W., Untch M. Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer. ESMO Open. 2022;7(4):100553. https://doi.org/10.1016/j.esmoop.2022.100553.

Availability: https://www.med-sovet.pro/jour/article/view/7665
https://doi.org/10.21518/ms2023-192

A Mathematical Model for Complete Morphological Regression in Primary Operable HER2-Positive Breast Cancer

Authors: A. E. Orlov, O. I. Kaganov, V. N. Saveliev, M. V. Tkachev, A. P. Borisov, P. L. Kruglova

Source: Креативная хирургия и онкология, Vol 11, Iss 1, Pp 5-9 (2021)

Subject Terms: her2-позитивный рак молочной железы, протоонкогена белки, трастузумаб, неоадъювантная химиотерапия, полный морфологический регресс, математическая модель, программа для эвм, Surgery, RD1-811, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.surgonco.ru/jour/article/view/562; https://doaj.org/toc/2307-0501; https://doaj.org/toc/2076-3093; https://doaj.org/article/312f4805d06f498abad4a5c4ca18d1e5

Availability: https://doi.org/10.24060/2076-3093-2021-11-1-5-9
https://doaj.org/article/312f4805d06f498abad4a5c4ca18d1e5

The role of the neoadjuvant approach in the treatment of primary operable HER2 positive breast cancer ; Роль неоадъювантного подхода в лечении первично операбельного HER2-позитивного рака молочной железы

Authors: M. A. Frolova, Е. V. Glazkova, A. V. Petrovsky, О. V. Krokhina, M. В. Stenina, S. A. Tyulyandin, М. А. Фролова, Е. В. Глазкова, А. В. Петровский, О. В. Крохина, М. Б. Стенина, С. А. Тюляндин

Source: Malignant tumours; Том 10, № 2 (2020); 45-52 ; Злокачественные опухоли; Том 10, № 2 (2020); 45-52 ; 2587-6813 ; 2224-5057

Subject Terms: HER2-позитивный рак молочной железы, HER2‑positive breast cancer

File Description: application/pdf

Relation: https://www.malignanttumors.org/jour/article/view/741/510; Rivenbark, A.G. Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine / A.G.Riverbank, S.M. O’Connor, W.B.Coleman //Am J Path. — 2013. — 183(4). — P. 1113 1124.; Cortazar, P. Pathological complete response and long term clinical benefit in breast cancer: the CTNeoBC pooled analysis / P. Cortazar, L. Zhang, M. Untch et al. // Lancet. — 2014. — Jul 12. — 384 (9938). — P. 164 72.; Baselga, J. Lapatinib with trastuzumab for HER2 positive early breast cancer (NeoALTTO): a randomised, open label, multicentre, phase 3 trial / J. Baselga, I. Bradbury, H. Eidtmann et al. // Lancet. — 2012. — 379. — P. 633 40.; Gianni, L. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, infl ammatory, or early HER2 positive breast cancer (NeoSphere): a randomised multicentre, open label, phase 2 trial / L. Gianni, T. Pienkowski, Y.H. Im et al. // Lancet Oncol. — 2012. — 13. — P. 25 32.; Schneeweiss, A. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline containing and anthracycline free chemotherapy regimens in patients with HER2 positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA) / A. Schneeweiss, S. Chia, T. Hickish et al. // Ann Oncol. — 2013. — 24. — P. 2278 2284.; Pegram, M.D. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer / M.D. Pegram, G.E. Konecny, C. O’Callaghan et al. // J Natl Cancer Inst. — 2004. — 96. — P. 739 49.; von Minckwitz, G. Neoadjuvant carboplatin in patients with triple negative and HER2 positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial / G. von Minckwitz, A. Schneeweiss, S. Loibl et al. // Lancet Oncol. — 2014. — 15(7). — 747e56.; Symmans, W.F. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy / W.F. Symmans, F. Peintinger, C. Hatzis et al. // J Clin Oncol. — 2007. — Oct 1. — 25(28). — P. 4414 22.; Untch, M. Neoadjuvant Treatment With Trastuzumab in HER2 Positive Breast Cancer: Results From the GeparQuattro Study / M. Untch, M. Rezai, S. Loibl et al. // JCO. — 2010. — Vol. 28, N 12. — April 20.; Denkert, C. Tumor Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2 Positive and Triple Negative Primary Breast Cancers / C. Denkert, G. von Minckwitz, J.C. Brase et al. // J Clin Oncol. — 2015. — Mar 20. — 33(9). — P. 983 91.; Hamy, A.S. Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease free survival in HER2 positive breast cancer /A.S. Hamy, J.Y. Pierga, A. Sabaila // Ann Oncol. — 2017. — 28. — P. 2233 2240.; Sheri, A. Residual proliferative cancer burden to predict longterm outcome following neoadjuvant chemotherapy /A. Sheri, I.E. Smith, S.R. Johnston // Ann Oncol. — 2015. — 26. — P. 75 80.; von Minckwitz, G. Trastuzumab Emtansine for Residual Invasive HER2 Positive Breast Cancer / G. von Minckwitz, C.S. Huang, M.S. Mano et al. // N Engl J Med. — 2019. — Feb 14. — 380(7). — P. 617 628.; https://www.malignanttumors.org/jour/article/view/741

Availability: https://www.malignanttumors.org/jour/article/view/741
https://doi.org/10.18027/2224-5057-2020-10-2-4

РАННИЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ.РАЗЛИЧНЫЕ АСПЕКТЫ КОМБИНИРОВАННОГО ЛЕЧЕНИЯ. НОВЫЕ ПОДХОДЫ К НЕОАДЪЮВАНТНОЙ ТЕРАПИИ РАННЕГО HER2 ПОЗИТИВНОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Authors: САКАЕВА ДИНА ДАМИРОВНА

Subject Terms: HER2-ПОЗИТИВНЫЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ,НЕОАДЪЮВАНТНАЯ ТЕРАПИЯ

File Description: text/html

Availability: http://cyberleninka.ru/article/n/ranniy-rak-molochnoy-zhelezy-razlichnye-aspekty-kombinirovannogo-lecheniya-novye-podhody-k-neoadyuvantnoy-terapii-rannego-her2
http://cyberleninka.ru/article_covers/15855705.png

Ранний рак молочной железы. Различные аспекты комбинированного лечения. Новые подходы к неоадъювантной терапии раннего her2 позитивного рака молочной железы

Source: Злокачественные опухоли.

Subject Terms: 03 medical and health sciences, 0302 clinical medicine, HER2-ПОЗИТИВНЫЙ РАК МОЛОЧНОЙ ЖЕЛЕЗЫ,НЕОАДЪЮВАНТНАЯ ТЕРАПИЯ

File Description: text/html

Access URL: http://cyberleninka.ru/article_covers/15855705.png
http://cyberleninka.ru/article/n/ranniy-rak-molochnoy-zhelezy-razlichnye-aspekty-kombinirovannogo-lecheniya-novye-podhody-k-neoadyuvantnoy-terapii-rannego-her2